GENERICS FOR VISION
Bridging the Accessibility Gap : Quality Care, Global Reach
While developing tomorrow's AI-driven breakthrough diagnostics, MedicVision is addressing today's urgent and critical eye care gaps across the Asia-Pacific region by delivering essential, high-quality generics.
Our commitment is to ensure that effective therapeutic solutions are within reach of every patient.
The Urgent Challenge:
A Crisis of Sight
The Asia-Pacific region bears a disproportionate burden of global vision impairment, creating an immediate need for quality, accessible treatments.
Maximizing Impact
We strategically target areas where accessible generics can deliver the most immediate and profound impact on patient health.
We are addressing;
13+
400%
>85%
60%
million Australians have chronic eye disease
surge in pediatric myopia during the pandemic
dry eye disease prevalence
global vision impairment cases concentrated in Asia-Pacific
Pediatric Myopia Control
Addressing the global childhood vision crisis with essential solutions to slow the progression of myopia.
Dry Eye Management
Providing effective, high-quality treatments for aging populations and those suffering from digital eye strain.
Retinal Health Solutions
Focusing on areas where 98% of blindness is preventable through early intervention and accessible medications.
Our Regional Focus
Our focus is on bringing strategic therapeutic solutions to healthcare providers across
Australia , New Zealand , Singapore , Malaysia , Indonesia , Thailand & Vietnam .
ANZ Region
Primary markets
AUSTRALIA & NEW ZEALAND​
Sophisticated market exceeding AUD 2 Billion annually, tackling high prevalence of dry eye (>85%) and the 400% surge in childhood myopia post-pandemic.
TGA regulatory approval provides a globally recognized quality stamp, drastically reducing registration timelines across the region.
Australian made generics ​
for vision management
​
Offering;
TGA Regulatory Credibility , Quality Assuarance , Supply Chain Reliability & Manufacturing Excellence